Evidence map›Paper›PMID 26402918›Full record

Trial reportJournal of clinical hypertension (Greenwich, Conn.)2016

LCZ696, a First-in-Class Angiotensin Receptor-Neprilysin Inhibitor: The First Clinical Experience in Patients With Severe Hypertension.

Kazuomi Kario, Yuko Tamaki, Naoko Okino, Hiromi Gotou, Min Zhu, Jack Zhang

Registry-linked trialAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical hypertension (Greenwich, Conn.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01646671 (A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension), which is not on this map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01646671 phase3completednot on this map

A Multi-center, Open Label Study for Evaluation of the Safety, Tolerability and Efficacy of 8-week Treatment With LCZ696 in Japanese Patients With Severe Hypertension

TypeinterventionalSponsorNovartis PharmaceuticalsRan2012 to 2013Enrolled35ConditionsSevere HypertensionArmsLCZ696
3 · Its place in the literature

Who cites it

25 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Observational
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Angiotensin receptor-neprilysin inhibitors: Comprehensive review and implications in hypertension treatment.Hypertension research : official journal of the Japanese Society of Hypertension · 2021
    Review
  12. Review
  13. Review
  14. Review
  15. Emerging Therapy in Hypertension.Current hypertension reports · 2019
    Review
  16. Article
  17. Article
  18. Review
  19. Benefits and pitfalls of sacubitril/valsartan treatment in patients with hypertension.Journal of clinical hypertension (Greenwich, Conn.) · 2018
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Kazuomi KarioJichi Medical University School of Medicine, Tochigi, Japan.
Yuko TamakiClinical Development, Novartis Pharma KK, Tokyo, Japan.
Naoko OkinoClinical Development, Novartis Pharma KK, Tokyo, Japan.
Hiromi GotouClinical Development, Novartis Pharma KK, Tokyo, Japan.
Min ZhuBeijing Novartis Pharma Co. Ltd, Beijing, China.
Jack ZhangNovartis Pharmaceuticals Corporation, East Hanover, NJ.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safety of LCZ696, a novel angiotensin receptor-neprilysin inhibitor, was evaluated for the first time in patients with severe hypertension in this 8-week, multicenter, open-label study. Thirty-five Japanese patients with either office systolic blood pressure (SBP) ≥180 mm Hg or diastolic blood pressure (DBP) ≥110 mm Hg received LCZ696 200 mg. If blood pressure was uncontrolled, the LCZ696 dose was increased to 400 mg after 2 weeks (if there were no safety concerns; n=32), followed by an optional addition of another antihypertensive drug (except angiotensin receptor blocker and angiotensin-converting enzyme inhibitor) after 4 weeks (n=21). Reductions in office SBP/DBP (baseline, 173.4 mm Hg/112.4 mm Hg) and pulse pressure (baseline, 61.0 mm Hg) at week 8 were 35.3/22.1 mm Hg and 13.2 mm Hg, respectively. The overall incidence of adverse events was 48.6% with no reports of dizziness, hypotension, or angioedema. The LCZ696-based regimen was generally well-tolerated and could present a treatment option for severe hypertension in Asian patients especially in reducing SBP and pulse pressure.

Indexed as

AgedAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsBlood PressureDose-Response Relationship, DrugDouble-Blind MethodDrug CombinationsFemaleFollow-Up StudiesHumansHypertensionMaleMiddle AgedNeprilysinSeverity of Illness IndexAminobutyratesAngiotensin Receptor AntagonistsBiphenyl CompoundsDrug CombinationsNeprilysinsacubitril and valsartan sodium hydrate drug combinationTetrazolesValsartan

Identifiers

PMID26402918
PMCPMC8032009

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.